Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
-
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
-
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
-
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
-
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Therapeutic Areas
